Evaluation of the bronchial arteries: normal findings, hypertrophy and embolization in patients with hemoptysis

João Almeida *, Cecília Leal and Luísa Figueiredo

Abstract

The enlargement of the bronchial arteries occurs in a multitude of congenital and acquired diseases and is responsible for the majority of cases of hemoptysis. In this review, we provide a simplified imaging approach to the evaluation of the bronchial arteries. We highlight the anatomy and function of the bronchial arteries, typical imaging findings, how to recognize bronchial artery dilatation, and its underlying causes. Contrast-enhanced computer tomography plays a major role in diagnosing bronchial artery enlargement and also improves treatment planning. Bronchial artery embolization has proven to be effective in controlling the potential hazardous hemoptysis.

Keywords: Bronchial arteries, Hemoptysis, Embolization, Computer tomography, Angiography

Key points

- Bronchial arteries most commonly originate from the descending thoracic aorta, although they may also have an ectopic origin from nearby arteries.
- Normal bronchial arteries are very thin (< 1.5 mm).
- The causes of bronchial artery dilatation are variable and include congenital and acquired diseases.
- Bronchial artery enlargement can be recognized when its caliber exceeds 2 mm, increasing the risk of clinically significant hemoptysis.
- Embolization is an effective technique in the management of patients with hemoptysis.

Introduction

The lungs have a dual vascular supply—pulmonary and bronchial. The pulmonary arteries have a major role in gas exchange, delivering deoxygenated blood to the lungs. The bronchial arteries have a supportive role, with a much thinner caliber than the pulmonary arteries, and they carry oxygenated blood to the bronchial tree, large blood vessels, lymph nodes, esophagus, and pleura [1]. The bronchial arteries have distal microvascular anastomoses connecting to the pulmonary arterial system [2].

Most of the time, in healthy patients, the bronchial arteries are very thin and difficult to detect on contrast-enhanced computer tomography (CECT) examinations. Some diseases may lead to an impairment of the pulmonary circulation. Bronchial arteries have a notable plasticity, potentially increasing its flow from 1 up to 30% of the cardiac output in response to a pulmonary insult. Consequently, bronchial artery hypertrophy (BAH) and dilatation of the thin-walled distal bronchial-to-pulmonary artery anastomosis may occur. However, this recruitment increases the risk of bronchial artery rupture with subsequent pulmonary hemorrhage [1]. Bronchial arterial system is the main source of bleeding in 90% of the cases of massive hemoptysis, followed by the pulmonary arteries (5%), and the non-bronchial systemic arteries (5%) [3].

CECT is valuable in patients with hemoptysis, allowing the visualization of dilated bronchial or non-bronchial
arteries potentially responsible for hemoptysis, providing a roadmap to guide the interventional approach.

The aim of this pictorial review is to familiarize the reader with the normal anatomy of the bronchial arteries and its most common variants, how to recognize BAH, underlying diseases, and finally, to discuss the role of bronchial artery embolization in patients with hemoptysis.

**Anatomy of bronchial arteries**

The anatomy of the bronchial arteries is quite variable in terms of origin and number. Normal bronchial arteries are small vessels, most commonly originating from the descending thoracic aorta (orthotopic), usually at the T5-T6 vertebral plane, 1–2 cm above or below the carinal level (Fig. 1).

In up to 36% of cases, they can originate elsewhere (ectopic), such as from the aortic arch, subclavian artery, thyrocervical trunk, internal mammary artery, and coronary arteries [4–7]. Ectopic bronchial arteries are recognized due to its adjacent course with the associated bronchi.

In its orthotopic origin, the right bronchial arteries preferentially arise from the posteromedial aortic wall, directly or more commonly (67% of cases) from a short intercostal-bronchial trunk (ICBT). The left bronchial arteries typically originate from the anterior or lateral aortic wall, both running towards each hilum with a retrotracheal course [8].

Cauldwell et al. described several variations in terms of the number and origin of the bronchial arteries, although four branching types were notably more prevalent (Fig. 2). The most common (type 1) is two left and one right bronchial artery, the latter originating from an ICBT, with a reported incidence of 41% [8, 9]. Other common variants include one artery in each side, the right bronchial artery originating from an ICBT (type 2), two right and two left bronchial arteries (type 3), and two right and one left bronchial arteries (type 4), respectively with 21%, 20%, and 10% of occurrence [9]. The normal caliber of the bronchial arteries is less than 1.5 mm near the origin and less than 0.5 mm distally, as they ramify in the pulmonary hila. When hypertrophy occurs, its diameter usually exceeds 2 mm, and they tend to have a more tortuous course. Venous bronchial drainage is mainly through the pulmonary veins, with a smaller contribution of drainage through the superior vena cava, azygos, and hemazygos systems [10].

**Imaging of bronchial arteries**

CECT frequently allows identification of the bronchial arteries and non-bronchial systemic arteries, particularly with modern scanners due to higher spatial resolution. In the evaluation of the bronchial arteries, CECT imaging should be acquired from the supraclavicular regions to the level of the renal arteries, depicting both orthotopic and ectopic bronchial arteries and possible collateral branches to the pulmonary arterial system.

Fig. 1 Origin of orthotopic bronchial arteries. Axial (a) and sagittal (b) CECT view of an orthotopic bronchial artery (black arrows) originating from the descending thoracic aorta (DA) at the T5–T6 vertebral plane, near the carinal level.
For improved assessment, CECT protocol should be optimized using high volume and high flow, usually with intravenous injection of 100–120 mL (1.2 mL/kg) of non-ionic contrast medium (350 mg/mL), at a rate of 3–4 mL/s via an antecubital vein. The acquisition benefits from a bolus-tracking technique, aiming for the higher enhancing phase of the descending thoracic aorta and the bronchial circulation (threshold of 120 HU). The imaging parameters are scanner-dependent, frequently with a beam width of 10 mm, beam pitch of 1.2–1.5, tube voltage of 80–120 kV, and a tube current of 90–140 mA (Table 1).

Cardiac gating and iterative model reconstruction can be useful in the reduction of motion artifacts and noise [11]. Dual-energy spectral CT with low kiloelectron volt monoenergetic reconstructions may also improve image quality, providing the best contrast-to-noise ratio for depicting the bronchial arteries [12].

A low-frequency reconstruction algorithm is preferred when assessing the bronchial arteries, increasing its conspicuity. The images should be reconstructed preferably with thin slices (≤ 1.25 mm), to avoid partial volume effect, and visualized in multiplanar reformats due to the tortuosity of the bronchial arteries [4, 10, 13]. Interactive maximum intensity projection (MIP) is a volume-rendering technique that can be useful when depicting small vessels like the bronchial arteries, displaying its tortuous course in a single image (Fig. 3b, d), being complementary to the axial images. Section thickness and obliquity of the reformatted images should be adjusted in each patient to accurately depict the involved vessels.

Normal bronchial arteries have a reduced caliber (< 1.5 mm) at their origin (Fig. 3a). At CECT, they appear as linear enhancing structures with an undulating or tortuous morphology in the mediastinum between its orthotopic origin and the retroesophageal/retrotracheal region (Fig. 3a). Sometimes, there are structures that can mimic bronchial arteries due to the proximity of its origin, especially in non-enhanced CT exams, such as regional lymph nodes or azygos vein. Axial images are essential to the initial approach and identification of the origin of bronchial arteries, and should be complemented with assessment of...

---

**Table 1** Multi-detector row CT parameters

| Parameters | Multi-detector row CT for bronchial artery evaluation |
|------------|------------------------------------------------------|
| Volume of interest | Supraclavicular regions to L2 (level of renal arteries) |
| Tube voltage | 80–120 kV |
| Tube current | 90–140 mA |
| Collimation | 64 x 0.6 mm |
| Pitch | 1.2–1.5 |
| Contrast material | |
| Volume | 100–120 mL |
| Concentration | 350 mg/mL |
| Injection rate | 3–4 mL/s |

Suggested multi-detector row CT parameters for bronchial artery evaluation
multiplanar and MIP images, particularly when evaluating the mediastinal or hilar tortuous course of the bronchial arteries.

Bronchial arteries larger than 2 mm are typically considered abnormally enlarged or hypertrophied, with an increased risk of bleeding (Fig. 3b, c, d) [7, 8, 14]. Even when their caliber is less than 2 mm, its traceability from the origin to the hilum is associated with bronchial arteries potentially causing hemoptysis [14]. Extravasation of contrast medium is a direct sign of bronchial hemorrhage, although it is infrequently seen, with reported prevalence of 4–11% [15].

**Causes of bronchial artery hypertrophy**

There is a multitude of congenital and acquired diseases that can lead to BAH. These include lung parenchymal diseases, airway-centered diseases, or pulmonary vascular diseases, which directly or indirectly cause a decrease in pulmonary blood flow, leading to chronic pulmonary ischemia. In response, the bronchial arterial system reacts with compensatory recruitment and hypertrophy, increasing lung perfusion through distal anastomoses with the pulmonary arterial system [2, 16].

In patients with BAH, it is important to understand the underlying cause [10]. We will briefly review the major causes of bronchial artery dilatation (Table 2) in the following sections.

**Congenital causes of BAH**

The most common congenital diseases associated with bronchial artery dilatation are Tetralogy of Fallot, pulmonary agenesis, and an anomalous left coronary artery arising from the pulmonary artery (ALCAPA syndrome). Tetralogy of Fallot is the most common cyanotic congenital heart condition. Classically, it is characterized by the combination of right ventricular outflow tract obstruction, ventricular septal defect, overriding aorta, and right ventricular hypertrophy [17]. When severe, it is associated

---

**Fig. 3** Imaging of the bronchial arteries. CECT findings of normal bronchial arteries (a, arrow), with a reduced caliber inferior to 1,5 mm. The remaining images show a patient with hypertrophy of the bronchial arteries, with a caliber exceeding 2 mm (b, c, d, arrows). MIP images (b, d) are useful when depicting small vessels like the bronchial arteries, displaying its tortuous course in a single image. The patient had a long-term history of bronchiectasis.
with pulmonary valve atresia, leading to an impairment of the pulmonary arterial flow. As a response, in cases of closed ductus arteriosus, pulmonary arterial circulation is partially assured by systemic fetal vessels called major aortopulmonary collateral arteries (MAPCAs) that persist after birth to compensate the impairment of the pulmonary circulation. MAPCAs usually originate from the descending thoracic aorta and probably represent dilated bronchial arteries due to its similar origin and course (Fig. 4a–c) [18]. MAPCAs are essential to assure the pulmonary circulation in such patients until undergoing a corrective surgical procedure, when they are frequently embolized. Hemoptysis may occur, potentially originating from the aneurismal dilation of hypertrophied bronchial vessels, erosion of varicose bronchial vessels into the airway, or rupture of MAPCAs [19, 20]. Hemoptysis may be triggered by infection or co-existing clotting disorders. When it compromises the hemodynamics stability of the patient, embolization of the culprit artery is indicated [17, 20].

Agenesis of the pulmonary artery, also called proximal interruption of the pulmonary artery, is an uncommon developmental anomaly resulting in proximal absence of the pulmonary artery, with preservation of the intrapulmonary vasculature. This variant can occur on either side, more commonly on the right side, with ipsilateral lung hypoplasia [21]. When it occurs, the distal pulmonary arterial branches are usually supplied by hypertrophied bronchial arteries, internal mammary, intercostal, subdiaphragmatic, or coronary arterial collaterals (Fig. 4d).

Table 2 Causes of BAH

| Congenital diseases       | Acquired diseases                  |
|---------------------------|------------------------------------|
| Tetralogy of Fallot       | Bronchiectasis                     |
| Pulmonary agenesis        | Cystic fibrosis                    |
| ALCAPA syndrome           | Tuberculosis                       |
|                           | Aspergilloma                       |
|                           | Lung abscess                       |
|                           | Chronic thromboembolic disease     |
|                           | Pulmonary hypertension             |
|                           | Takayasu arteritis                 |
|                           | Fibrosing mediastinitis            |
|                           | Malignancy                         |

List of the most common congenital and acquired diseases associated with BAH

Fig. 4 Congenital causes of BAH—Tetralogy of Fallot and pulmonary agenesis. Significant bronchial artery hypertrophy (white arrows) in a patient with tetralogy of Fallot (a–c) and in a patient with pulmonary artery agenesis (d)—"image b" shows a ventricular septal defect, overriding aorta and right ventricular hypertrophy, features of tetralogy of Fallot. The black arrow in “image d” depicts the absence of the pulmonary artery. RV, right ventricle; LV, left ventricle; AA, ascending aorta
Clinical presentation varies from asymptomatic incidental finding to massive hemoptysis due to ruptured hypertrophied systemic collaterals, rarely requiring transcatheter embolization [21].

ALCAPA syndrome is a rare congenital disease associated with an anomalous origin of the left coronary artery from the pulmonary artery trunk, leading to a right-to-left shunting. It has a high mortality rate due to myocardial infarction, explained by the diverted flow from the coronary bed to the pulmonary trunk. This is counterbalanced by the development of right coronary to left coronary artery collaterals early in life. It may be asymptomatic, being diagnosed later in childhood. In these patients, bronchial artery dilatation occurs to increase the arterial supply to the left coronary territory (Fig. 5) [22, 23].

Acquired causes of BAH
There are several acquired diseases that can cause bronchial artery hypertrophy.

Inflammatory diseases and infection, such as bronchiectasis (Fig. 6), cystic fibrosis (Fig. 7), tuberculosis (TB), or aspergilloma (Fig. 8), may be associated with BAH. The proposed mechanism is complex, probably due to vasculitis with increased neovascularity and microvascular thrombosis of the pulmonary vessels [24, 25]. This process appears to be mediated by angiogenic growth factors, which promote the proliferation and expansion of the bronchial arteries [24].

Bronchiectasis is an acquired disorder characterized by permanent abnormal dilatation and destruction of the bronchial walls. Its pathophysiology involves an infectious insult to the airways, with impaired drainage, airway obstruction, and/or a defect in host defense. There is a multitude of etiologies associated with bronchiectasis, such as cystic fibrosis, cigarette smoking, pulmonary infections, defective host defenses, and foreign-body airway obstruction. Recurrent airway inflammation promotes neovascularity and bronchial artery dilatation, increasing the risk of hemoptysis (Figs. 6 and 7) [25].

Infection is also associated with BAH, and one of the most common agent is Mycobacterium tuberculosis. Nowadays, despite recent medical advances, TB remains a relevant health burden, particularly in developing countries. Historically, hemoptysis was considered almost pathognomonic for pulmonary tuberculosis. Hemoptysis is a potential complication of active or prior TB. Bleeding in active TB can occur in the setting of cavitary or noncavitary disease and usually results from bronchial arterial ulceration, with necrosis of adjacent blood vessels. Rarely, active TB can cause hemoptysis due to rupture of a Rasmussen’s aneurysm, which is a pseudo-aneurysm of the

---

**Fig. 5** Congenital causes of BAH—ALCAPA syndrome. Patient with an ALCAPA syndrome. CECT showing an anomalous left coronary artery arising from the pulmonary artery (a, black arrow) with associated bronchial artery dilatation (white arrows). PA, pulmonary artery; DA, descending aorta.
pulmonary artery adjacent to a tuberculous cavity. When it occurs, it may lead to life threatening massive hemoptysis, with associated high mortality rate (Fig. 8) [26].

Although strongly associated with active pulmonary TB, hemoptysis can also present following resolution of an acute disease (post-primary TB) due to airway or lung parenchymal distortion with associated vascular changes. This irreversible process leads to distortion and damage of local bronchial vascularization, which becomes hypertrophied, dilated, and exposed, with increased risk of bleeding. Other causes of hemoptysis in the setting of inactive/prior TB include the erosion of a healed calcified lymph node through a bronchial artery, bronchiectasis due to structural lung damage, and fungal colonization of prior lung cavities with Aspergillus or other species, leading to hemoptysis due to erosion of adjacent vasculature (Fig. 9) [26, 27].

Other lung infections, particularly lung abscess, can also cause hemoptysis. Bleeding may occur acutely from direct necrosis of lung tissue or in the setting of chronic inflammation, due to rupture of hypertrophied bronchial arteries [27].

BAH is a potential finding in patients with thromboembolic disease. When it occurs, the presence of dilated bronchial arteries favors chronic disease, and usually coexists on CECT with other vascular signs of chronic thromboembolic disease, such as endoluminal peripheral filling defect with obtuse margins, calcified thrombus, or a web/linear morphology (Fig. 10) [28–30].

Secondary findings include signs of pulmonary hypertension, with increased caliber of the pulmonary arterial trunk, enlargement of the right heart cavities, and parenchymal changes with subpleural linear or wedge-shaped opacities and mosaic attenuation.

Due to chronic pulmonary ischemia, increased incidence of BAH has been reported in chronic thromboembolic disease, potentially associated with moderate-to-massive hemoptysis in 0.1% of the cases [31].

The management of hemoptysis in these patients is challenging due to the ongoing anticoagulant therapy, so even in cases of mild hemoptysis, intervention with embolization should be considered [32].
Pulmonary hypertension is a progressive disease characterized by an elevated pulmonary artery pressure (≥ 25 mmHg at rest). According to its etiology, it is classified as primary, also called pulmonary arterial hypertension (PAH), or secondary, when associated with other diseases like pulmonary thromboembolism, left heart disease, or chronic lung disease.

PAH is primarily a disease of the pulmonary circulation. It is rare, with an estimated incidence of 5–15 cases per one million, being more common in young adults [33]. It affects the small pulmonary muscular arterioles, leading to vasoconstriction, hyperplasia, fibrosis, and thrombosis. It is a severe and progressive disease, with a median survival of 2.8 years if untreated. Common

![Image](image-url)

**Fig. 7** Acquired causes of BAH—cystic fibrosis. Ectopic dilated bronchial artery arising from the distal portion of the aortic arch (a, b, arrows) in a patient with cystic fibrosis. Typical pulmonary manifestations of cystic fibrosis are well depicted in the image (c).

![Image](image-url)

**Fig. 8** Rasmussen’s aneurysm. Active TB can cause hemoptysis due to rupture of a Rasmussen’s aneurysm (a, white arrow), which is a pseudoaneurysm of the pulmonary artery adjacent to a cavity in patients with pulmonary TB (b).
imaging findings of PAH include enlargement of the pulmonary arterial trunk (> 29 mm), narrowing of the distal pulmonary arteries and associated signs of right heart strain. Although rare, BAH is a possible finding in PAH, with a reported incidence of 14%, increasing the risk of hemoptysis [34]. The mechanism of BAH in PAH is not fully understood, being probably related to tissue hypoxia with compensatory hypertrophy of the bronchial arteries. The association of BAH and hemoptysis might be related to the frailty of the hypertrophied bronchial arteries, with more tendency to rupture [35].

The number of dilated bronchial arteries appears to be linked to the increasing severity of the pulmonary arterial hypertension, as a response of the bronchial vasculature to the increasing resistance of flow in the damaged pulmonary vasculature.

Interestingly, patients with non-thromboembolic pulmonary hypertension have a much lower incidence of BAH (10–26%), compared with chronic thromboembolic disease (> 90%). This fact may be helpful in differentiating both diseases [34].

Takayasu arteritis is classified as a large-vessel vasculitis, affecting the aorta, its primary branches, and the pulmonary arteries. It mostly affects young females, usually between 10 and 40 years of age. The pathophysiology is poorly understood, probably related to cell-mediated mechanisms with infiltration of inflammatory cells in the large-vessel walls, leading to vessel narrowing, occlusion, or dilatation of the involved arteries. Imaging findings in the acute phase include large-vessel wall thickening with contrast enhancement, progressing to stenosis, or occlusion in the late phase. Bronchial artery enlargement in Takayasu arteritis is a late finding, with increased risk of hemoptysis, occurring only in patients with marked pulmonary artery stenosis or occlusion, due to chronic hypoxemia of the lung tissue [36, 37].

Fibrosing mediastinitis is an infiltrative benign process with excessive fibrotic reaction in the mediastinum, causing central obstruction of the pulmonary vessels. It is frequently sequelae of a prior local nodal infection, usually histoplasmosis, with associated residual mediastinal calcifications [38]. It can result in compromise of the airway, the esophagus, and the great vessels, with reduction of the pulmonary blood flow when it encases the pulmonary vessels. The process is generally unilateral, with ipsilateral bronchial artery dilatation to the affected site as a compensatory response to lung hypoxemia [39, 40].

Malignancy, in particular lung cancer, is a common cause of hemoptysis in older patients, being responsible for almost 25% of all cases of hemoptysis in the USA [41].

Fig. 9 Acquired causes of BAH—tuberculosis and aspergilloma. Left bronchial artery enlargement (a, white arrow) in a patient with an aspergilloma complicating a left upper lobe cavity from tuberculosis (c). Image b represents the same patient 4 years before demonstrating an aerated cavity without signs of fungal colonization.
The highest incidence of bleeding occurs with squamous cell carcinoma, followed by adenocarcinoma, small cell, and large cell carcinoma [42]. The possible sources of bleeding include bronchial arterial bleed within the tumor, tumor erosion into the pulmonary artery, or systemic arterial rupture.

The widespread use of bronchial artery embolization in the management of hemoptysis contributed to a decrease of the mortality rate, with a success rate of 77–82% in immediate bleeding control [43, 44].

Hemoptysis

Hemoptysis, the expectoration of blood from the lower respiratory tract, is a worrying symptom, usually associated with an underlying lung disease. It can vary from a self-limiting mild blood-streaking of sputum to a massive life-threatening hemoptysis, although there is no universal consensus about the blood volume criteria defining the degree of hemoptysis. This is partially explained by the difficulty to quantify the amount of expectorated blood. The term massive hemoptysis is generally reserved for life-threatening situations, associated with airway obstruction, abnormal gas exchange, or hemodynamic instability [45]. As stated before, there is a multitude of diseases that can cause BAH, increasing the risk of hemoptysis.

The most frequent diseases causing hemoptysis are TB, bronchiectasis, and lung cancer [45–47].

Infection, in particular TB, remains one of the main causes of hemoptysis, especially in geographic areas with a higher TB incidence.
According to a study of Agmy et al. from Egypt, which included 341 patients with moderate to severe hemoptysis who underwent bronchial artery embolization, TB (either active or sequelae) was the most common etiology of hemoptysis with an incidence of 57%, followed by bronchiectasis (22%) and aspergilloma (8%) [47]. In terms of absolute frequency, bronchiectasis and malignancy were considered the main causes of hemoptysis in some recently reported studies carried in Greece, South Korea, and Italy, with a lower incidence of TB, probably related to geographical differences [45, 46].

Noninvasive imaging has an important role in patients with hemoptysis, allowing the identification of the underlying cause and potential site of bleeding, improving the treatment approach.

Historically, chest radiography has been useful in the initial imaging approach of patients with hemoptysis. It is readily available, quick, and inexpensive, potentially revealing the side of the process or underlying abnormalities such as cavitation, masses, or chronic lung disease.

However, it has a low sensibility, with reported positive diagnostic yield of only 50%. It identifies the bleeding site in only 46% of cases, in contrast to CECT, which may reveal the bleeding site in 63 to 100% of patients with hemoptysis [46].

CECT is a valuable technique in the clinical context of hemoptysis, allowing a comprehensive analysis of the lung parenchyma, airway, and thoracic vasculature using contrast material. It can depict bronchial artery hypertrophy (most common origin up to 90%) or other potential sites of hemorrhage, underlying diseases and helps to plan the treatment approach (Fig. 11) [48]. When performed before treatment, CECT may reveal the number and origin of the bronchial arteries and possible coexistence of non-bronchial collaterals. A recent study of Lin et al. evaluated the diagnostic performance of CECT in depicting bronchial and non-bronchial systemic arteries in 52 patients with hemoptysis and the feasibility of angiographic embolization. CECT correctly identified 97% of the pathological arteries and facilitated the angiographic approach by revealing its origin, particularly when multiple [49].

CECT is able to identify ectopic vessels amenable for embolization, which potentially reduce recurrence rate of hemoptysis, embolization procedure time, and iatrogenic risks when searching for abnormal vessels in the setting of embolization [50].

Findings of pulmonary hemorrhage on CECT are variable and include airspace opacities varying from ground glass to consolidation, smooth interlobular septal thickening, “crazy-paving” pattern, or centrilobular nodules (Fig. 12). The presence of endobronchial filling material may guide the identification of bleeding site [1].

In summary, CECT has proven its value in the context of hemoptysis, not only allowing the identification of underlying cause and site of bleeding, but also providing a detailed knowledge of the arterial bronchial and non-bronchial anatomy, essential for guiding the endovascular treatment approach.
Bronchial artery embolization

When BAH occurs, the risk of pulmonary hemorrhage increases, ranging from a small to a potential life-threatening hemoptysis [51].

Bronchial artery embolization is a safe and well-tolerated approach, less invasive than surgery, with proven results in controlling clinically significant hemoptysis [48, 50].

Angiographic approach usually begins with femoral artery cannulation, followed by an aortography of the descending thoracic aorta for identification of bronchial artery and collaterals origin. Ascending aortography and selective subclavian/innominate arteriography are also advocated for identifying apical collaterals. In patients with prior CECT, aortography might be dismissed. Selective catheterization of the bronchial arteries is frequently carried out with 4 or 5 French catheters, facilitated by a reverse-curve catheter configuration. Left main stem bronchus is a common landmark of the level of bronchial artery origin.

Angiography of the bronchial arteries is usually performed with a flow rate of 2–3 mL/s. After selective bronchial arteriogram, supporting features sensitive for localization of hemoptysis include vascular hypertrophy, tortuosity, hypervascularity, vascular shunting, or extravasation (Fig. 13) [48, 51].

Possible major complications of bronchial artery embolization include transverse myelitis, bronchial infarction, or esophagobronchial fistula. Minor complications

Fig. 12 CT findings of pulmonary hemorrhage. Hazy ground-glass infiltrates (a, b, c) representing intra-alveolar hemorrhage in patients with hemoptysis. Also note endobronchial filling in b and crazy paving pattern in d

Fig. 13 Bronchial artery embolization. Selective catheter angiography before (a) and after (b) successful right bronchial artery embolization in a patient with hemoptysis in the context of chronic thromboembolic disease
are also possible, such as transient chest pain or dysphagia. The most feared complication is spinal cord ischemia related to accidental embolization of a spinal artery, fortunately rare (< 5%) [51].

When performing the embolization, the interventionalist must be cautious with non-target spinal vessels such as the Adamkiewicz artery, the largest anterior medullary branch of the anterior spinal artery. It typically arises from a left posterior intercostal artery at T8–T12 or rarely from T5–T8, with a characteristic hairpin turn or a vertical descent course, and its accidental embolization can have devastating consequences [52]. Therefore, meticulous technique, the use of microcatheters in a coaxial system and distal positioning to the expected location of the spinal artery feeders, can minimize the risk of spinal artery embolization. Superselective embolization is also more effective, improving treatment durability [53].

Polyvinyl alcohol (PVA) particles are commonly used for embolization, ranging from 300 to 700 μm in size. Small particles (< 200 μm) should be avoided because of the increased risk of spinal artery embolization compared with larger particles (> 300 μm) [14, 51].

After embolization of the aimed vascular territory to stasis or near stasis, a reduction in size and enhancement of the bronchial arteries are common findings (Fig. 14).

Bronchial artery embolization has proven to be effective in controlling the potential hazardous hemoptysis, with success rates between 73 and 100% [1, 7, 27, 50]. Nonetheless, long-term recurrence rate of hemoptysis is not neglectable, particularly in patients with TB and aspergilloma, ranging from 10 to 33%. If necessary, in

![Fig. 14 CECT findings of bronchial arteries before and after embolization. After an effective bronchial artery embolization, absence of enhancement (c, black arrow) and caliber reduction (d, black arrow) are usual CECT findings. We can compare it to the imaging findings before the embolization (a, b, white arrows).](image-url)
cases of recurrence, re-embolization is adequate in the management of hemoptysis, with similar clinical success compared with the initial embolization procedure [54, 55].

Conclusion
Radiologists must be familiar with the anatomy of the bronchial arteries. They must be able to recognize when bronchial artery dilatation is present, identify possible underlying diseases, and consider the possibility of bronchial artery embolization in cases of uncontrollable hemoptysis.

Radiologists play a major role in the management of these patients, allowing for the better outcome, particularly in hazardous situations.

Abbreviations
AA: Ascending aorta; ALCAPA: Anomalous left coronary artery arising from the pulmonary artery; BAH: Bronchial artery hypertrophy; CECT: Contrast-enhanced computer tomography; CT: Computer tomography; DA: Descending aorta; ICA: Intercostal artery; ICBT: Intercostal-bronchial trunk; LBA: Left bronchial artery; MAPCAs: Major aortopulmonary collateral arteries; MIP: Maximum intensity projection; PA: Pulmonary artery; PVA: Polyvinyl alcohol; RBA: Right bronchial artery; TB: Tuberculosis

Authors’ contributions
All authors equally contributed in writing the manuscript. All authors read and approved the final manuscript.

Funding
No funding

Availability of data and materials
All data and materials presented were from our hospital and daily practice.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests

Received: 9 March 2020 Accepted: 21 April 2020
Published online: 19 May 2020

References
1. Bruzzì JF, Rémy-Jardin M, Delhaye D, Teisseire A, Khalil C, Rémy J Multi-detector row CT of hemoptysis. Radiographics 26:3–22
2. Pump KK (1972) Distribution of bronchial arteries in the human lung. Chest 62:447–451
3. Jean-Baptiste E (2000) Clinical assessment and management of massive hemoptysis. Crit Care Med. 28:1642–1647
4. Tanoukht W, Tanisako K (2003) Radiographic relationship of the origin of the bronchial arteries to the left main bronchus. J Thorac Imaging 18:27–33
5. Hartmann IL, Remy-Jardin M, Menchini L, Teisseire A, Khalil C, Remy J Ectopic origin of bronchial arteries: assessment with multidetector helical CT angiography. Eur Radiol 17:1943–1953
6. Sancho C, Escalante E, Dominguez J et al (1998) Embolization of bronchial arteries of anomalous origin. Cardiovasc Intervent Radiol 21:300–304
7. Cohen AM, Doershuk CF, Stern RC (1990) Bronchial artery embolization to control hemoptysis in cystic fibrosis. Radiology 175:401–405
8. Morita Y, Takase K, Ichikawa H et al (2010) Bronchial artery anatomy: preoperative 3D simulation with multidetector CT. Radiology 255:934–943
9. Cauldwell EW, Siekert RG (1948) The bronchial arteries; an anatomic study of 150 human cadavers. Surg GynecoI Obstet 86:395–412
10. Furuse M, Saito K, Kunieda E et al (1987) Bronchial arteries: CT demonstration with angiographic correlation. Radiology 162:393–398
11. Gang G, Xu J, Wang J, Hao P, Xu Y (2017) Electrocardiography-gated computed tomography of the bronchial arteries with iterative image reconstruction: clinical evaluation and image quality. J Comput Assist Tomogr 41:970–975
12. Ma G, He T, Yu Y, Duan H, Yang C (2016) Improving image quality of bronchial arteries with virtual monochromatic spectral CT images. PLoS One 11:e0150985
13. Yener Ö, Türkvatan A, Yuçe G, Yener AU (2015) The normal anatomy and variations of the bronchial arteries: evaluation with multidetector computed tomography. Can Assoc Radiol J 66:44–52
14. Yoon W, Kim JK, Kim YH et al (2013) Bronchial and nonbronchial systemic artery embolization in management of hemoptysis: experience with 348 Patients. ISRN Vascular Medicine https://doi.org/10.1155/2013/262359
15. Ramakantan R, Bandekar VG, Gandhi MS, Aulakh BG, Deshmukh HL (1996) Massive hemoptysis due to pulmonary tuberculosis: control with bronchial artery embolization. Radiology 200:691–694
16. Walker CM, Rosado-de-Christenson ML, Martínez-Jimenez S, Kunin JR, Wilbie BC (2015) Bronchial arteries: anatomy, function, hypertrophy, and anomalies. Radiographics 35:32–49
17. Gonzalez J, Ruperez JA, Garcia Almagro FJ, Garcia Medina J, Capel A, Valdes M (2001) Tetralogy of Fallot complicated by severe hemoptysis in the adult. Rev Esp Cardiol 54:1002–1004
18. Nørgaard MA, Alphonso N, Cochrane AD, Menahem S, Brizard CP, d’Udekem Y (2000) Major aorto-pulmonary collateral arteries of patients with pulmonary atresia and ventricular septal defect are dilated bronchial arteries. Eur J Cardiothorac Surg 26:653–658
19. Suzuki Y, Fukuda I, Kohno M, Ikuya T, Wada M, Tsutsui T (1990) Preoperative therapeutic embolization for massive hemoptysis from bronchial collaterals in tetralogy of Fallot – a case report successfully treated by total correction. Nihon Kyobu Geka Gakkai Zasshi 38:472–476
20. van der Weijden P, Baur LH, Kool LJ, Vliegen HW, van der Wall EE (1998) Embolization as a treatment of life-threatening haemoptysis in an adult with tetralogy of Fallot with pulmonary atresia. Int J Card Imaging 14:123–126
21. Williams EA, Cox C, Chung JH, Grage RA, Rojas CA (2019) Proximal interruption of the pulmonary artery. J Thorac Imaging 34:56–64
22. Peña E, Nguyen ET, Merchant N, Dennie C (2009) ALCAPA syndrome: not just a pediatric disease. Radiographics 29:553–565
23. Karolczak MA, Wieteska J, Bec L, Madry W (2001) Anomalous origin of the left coronary artery (LCA) from pulmonary trunk (Bland-White-Garland syndrome) with systemic collateral supply to LCA. Med Sci Monit 7:755–758
24. McDonald DM (2001) Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 164:39–45
25. Osio S, Wear C, Hudson R et al (2012) A friend to the airways: a review of electrocardiography-gated CT of hemoptysis. Radiographics 32:1004–1019
26. Osiro S, Wear C, Hudson R et al (2012) A friend to the airways: a review of electrocardiography-gated CT of hemoptysis. Radiographics 32:1004–1019
27. Cahill BC, Ingbang DH (1994) Massive hemoptysis: Assessment and management. Clin Chest Med 15:147–167
28. Hasegawa I, Boiselle PM, Hatabu H (2014) Bronchial artery dilatation on MDCT scans of patients with acute pulmonary embolism: comparison with chronic or recurrent pulmonary embolism. AJR Am J Roentgenol 192:862–72
29. Pengo V, Lensing AW, Prins MH et al (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264
30. Kasai T, Chiba S (1979) Macroscopic anatomy of the bronchial arteries. Anat Anz 145:166–181
31. Rasmussen V, Moore W (1868) On haemoptysis, especially when fatal, in its anatomical and clinical aspects. Edinb Med J 14:486–503
32. Cahill BC, Ingbang DH (1994) Massive hemoptysis: Assessment and management. Clin Chest Med 15:147–167
33. McGoon MD, Benza RL, Escribano-Subias P et al (2013) Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 62:51–59
34. Remy-Jardin M, Duhamel A, Deken V, Dumont P, Remy J (2005) Systemic collateral supply in patients with chronic thromboembolic and pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264
35. McDonald DM (2001) Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 164:39–45
36. Osiro S, Wear C, Hudson R et al (2012) A friend to the airways: a review of electrocardiography-gated CT of hemoptysis. Radiographics 32:1004–1019
37. Cahill BC, Ingbang DH (1994) Massive hemoptysis: Assessment and management. Clin Chest Med 15:147–167
38. Hasegawa I, Boiselle PM, Hatabu H (2014) Bronchial artery dilatation on MDCT scans of patients with acute pulmonary embolism: comparison with chronic or recurrent pulmonary embolism. AJR Am J Roentgenol 192:862–72
39. Pengo V, Lensing AW, Prins MH et al (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264
40. Kasai T, Chiba S (1979) Macroscopic anatomy of the bronchial arteries. Anat Anz 145:166–181
41. Rasmussen V, Moore W (1868) On haemoptysis, especially when fatal, in its anatomical and clinical aspects. Edinb Med J 14:486–503
42. Cahill BC, Ingbang DH (1994) Massive hemoptysis: Assessment and management. Clin Chest Med 15:147–167
primary pulmonary hypertension: assessment with multi-detector row helical CT angiography. Radiology 235:274–281

35. Grubstein A, Benjaminov O, Dayan DB, Shritrit D, Cohen M, Kramer MR (2008) Computed tomography angiography in pulmonary hypertension. Isr Med Assoc J 10:117–120

36. Toledano K, Gualnik L, Lorber A et al (2011) Pulmonary arteries involvement in Takayasu’s arteritis: two cases and literature review. Semin Arthritis Rheum 41:461–470

37. Matsunaga N, Hayashi K, Sakamoto I, Ogawa Y, Matsumoto T (1997) Takayasu arteritis: protein radiologic manifestations and diagnosis. Radiographics 17:579–594

38. Goodwin RA, Nickell JA, Des Prez RM (1972) Mediastinal fibrosis complicating healed primary histoplasmosis and tuberculosis. Medicine (Baltimore) 51:227–246

39. Denlinger CE, Fernandez FG, Patterson GA, Kreisel D (2009) Fibrosing mediastinitis associated with complete occlusion of the left main pulmonary artery. Ann Thorac Surg 87:323

40. McNeeley MF, Chung JH, Bhalla S, Godwin JD (2012) Imaging of granulomatous fibrosing mediastinitis. AJR Am J Roentgenol 199:319–327

41. Reisz G, Stevens D, Boutwell C, Nair V (1997) The causes of hemoptysis revisited. A review of the etiologies of hemoptysis between 1986 and 1995. Mo Med 94:633–635

42. Miller RR, McGregor DH (1980) Hemorrhage from carcinoma of the lung. Cancer 46:200–205

43. García-Olivé I, Sanz-Santos J, Centeno C et al (2014) Predictors of recanalization in patients with life-threatening hemoptysis requiring artery embolization. Arch Bronconeumol 50:51–56

44. Fujita T, Tanabe M, Moritani K, Matsunaga N, Matsumoto T (2014) Immediate and late outcomes of bronchial and systemic artery embolization for palliative treatment of patients with non-small cell lung cancer having hemoptysis. Am J Hosp Palliat Care 31:602–607

45. Mondori M, Carlucci P, Job S et al (2018) Observational, multicentre study on the epidemiology of haemoptysis. Eur Respir J 4:51

46. Tsoumakidou M, Chrysofakis G, Tsiligianni I, Maltezakis G, Siafakas NM, Tzanakis N (2006) A prospective analysis of 184 hemoptysis cases: diagnostic impact of chest X-ray, computed tomography, bronchoscopy. Respiration 73:808–14.

47. Agmy GM, Wafy SM, Mohamed SA, Gad YA, Mustafa H, Abd El-Aziz AE (2010) Bronchial and nonbronchial systemic artery embolization in management of hemoptysis: experience with 348 Patients. Chest 138:265

48. Sidhu M, Wieseler K, Burdick T, Shaw D (2008) Bronchial artery embolization for hemoptysis. Semin Intervent Radiol 25:310–318

49. Lin Y, Chen Z, Yang X et al (2013) Bronchial and non-bronchial systemic arteries: value of multidetector CT angiography in diagnosis and angiographic embolisation feasibility analysis. J Med Imaging Radiat Oncol 57:644–651

50. Larici A, Franchi P, Occhipinti M et al (2014) Diagnosis and management of hemoptysis. Diagn Interv Radiol 20:299–309

51. Burke CT, Mauro MA (2004) Bronchial artery embolization. Semin Intervent Radiol 21:43–48

52. Bown A, Ray C (2012) Anterior spinal cord infarction following bronchial artery embolization. Semin Intervent Radiol 29:241–244

53. Tanaka N, Yamakado K, Murashima S et al (1997) Superselective bronchial artery embolization for hemoptysis with a coaxial microcatheter system. J Vasc Interv Radiol 8:65–70

54. Lee S, Chan JW, Chan SC et al (2008) Bronchial artery embolisation can be equally safe and effective in the management of chronic recurrent haemoptysis. Hong Kong Med J 14:14–20

55. Kato H, Kishikawa T, Yamada H, Matsumoto S, Kudo S (1990) Recurrent bleeding after arterial embolization in patients with hemoptysis. Chest 97: 541–546

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.